Researchers from the University of Sheffield and Sheffield Teaching Hospitals found the osteoporosis drug, denosumab, could protect patients from osteolysis, reduce the need for re-operations, and reduce the health burden of this disease.
European regulators have expanded the treatment scope of Amgen’s Xgeva to include the prevention of skeletal-related events in adults with multiple myeloma.